AI Engines For more Details: Perplexity Kagi Labs You
Bronchodilation: Khellin has been investigated for its bronchodilatory effects, which means it may help widen the airways in the lungs. This property has led to its exploration in the treatment of respiratory conditions such as asthma.
Antispasmodic: Khellin has been reported to possess antispasmodic properties, which could make it useful in alleviating muscle spasms or cramps.
Vasodilation: Some studies suggest that khellin may have vasodilatory effects, meaning it can widen blood vessels. This property could potentially be beneficial in conditions where improved blood flow is desired, such as certain cardiovascular conditions.
Phototherapy: Khellin has been studied for its photosensitizing properties, particularly in combination with ultraviolet A (UVA) light. This combination, known as PUVA therapy (psoralen combined with ultraviolet A), has been used in the treatment of certain skin conditions like psoriasis and vitiligo.
Antimicrobial: There is some evidence to suggest that khellin may possess antimicrobial properties, although further research is needed to fully understand its potential in this area.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| Taxonomy | Rank | Effect | Citations | Notation |
|---|---|---|---|---|
| Roseburia | genus | Decreases | 👪 Source Study | |
| Ruminococcus | genus | Decreases | 👪 Source Study | |
| Agathobacter | genus | Decreases | 👪 Source Study | |
| Clostridioides | genus | Decreases | 👪 Source Study | |
| Coprococcus | genus | Decreases | 👪 Source Study | |
| Eggerthella | genus | Decreases | 👪 Source Study | |
| Mediterraneibacter | genus | Decreases | 👪 Source Study | |
| Ruminococcus bromii | species | Decreases | 📓 Source Study | |
| Agathobacter rectalis | species | Decreases | 📓 Source Study | |
| Roseburia hominis | species | Decreases | 📓 Source Study | |
| Clostridioides difficile | species | Decreases | 📓 Source Study | Colitis |
| [Ruminococcus] torques | species | Decreases | 📓 Source Study | |
| Coprococcus comes | species | Decreases | 📓 Source Study | |
| Eggerthella lenta | species | Decreases | 📓 Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0 | 0 |
| ADHD | 1.1 | 0.6 | 0.83 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergies | 0.6 | 0.7 | -0.17 |
| Allergy to milk products | 0.6 | 0.6 | |
| Alzheimer's disease | 0.3 | 1.6 | -4.33 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | 0 |
| Ankylosing spondylitis | 0.3 | -0.3 | |
| Anorexia Nervosa | 0.3 | 1.1 | -2.67 |
| Asthma | 0.6 | 0.5 | 0.2 |
| Atherosclerosis | 0.3 | 0.5 | -0.67 |
| Atrial fibrillation | 0.9 | 0.1 | 8 |
| Autism | 1.5 | 1.2 | 0.25 |
| Autoimmune Disease | 0.5 | -0.5 | |
| Bipolar Disorder | 0.6 | 1.4 | -1.33 |
| Brain Trauma | 0.8 | -0.8 | |
| Carcinoma | 0.6 | 0.3 | 1 |
| Celiac Disease | 0.3 | -0.3 | |
| Cerebral Palsy | 0.8 | -0.8 | |
| Chronic Fatigue Syndrome | 1 | 0.7 | 0.43 |
| Chronic Kidney Disease | 0.4 | 0.9 | -1.25 |
| Chronic Lyme | 0.1 | 0.5 | -4 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.8 | -1.67 |
| Coagulation / Micro clot triggering bacteria | 0.8 | -0.8 | |
| Cognitive Function | 0.8 | 0.5 | 0.6 |
| Colorectal Cancer | 1.1 | 0.8 | 0.38 |
| Constipation | 0.3 | 0.5 | -0.67 |
| Coronary artery disease | 0.6 | 0.9 | -0.5 |
| COVID-19 | 0.6 | 2.2 | -2.67 |
| Crohn's Disease | 1.4 | 1.2 | 0.17 |
| cystic fibrosis | 0.5 | -0.5 | |
| deep vein thrombosis | 1.1 | 0.8 | 0.38 |
| Depression | 1.4 | 1.6 | -0.14 |
| Endometriosis | 0.3 | 1.1 | -2.67 |
| Fibromyalgia | 0.8 | 0 | 0 |
| Functional constipation / chronic idiopathic constipation | 0.6 | 1.2 | -1 |
| gallstone disease (gsd) | 0.3 | 0.5 | -0.67 |
| Generalized anxiety disorder | 0.6 | 0.3 | 1 |
| Gout | 0.3 | 0.6 | -1 |
| Graves' disease | 0.3 | 1.1 | -2.67 |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.9 | 0 | 0 |
| Heart Failure | 0.6 | 0.9 | -0.5 |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hypertension (High Blood Pressure | 0.3 | 1.2 | -3 |
| Hypothyroidism | 0.6 | -0.6 | |
| IgA nephropathy (IgAN) | 0.6 | 0.5 | 0.2 |
| Inflammatory Bowel Disease | 0.4 | 1.9 | -3.75 |
| Insomnia | 0.3 | 1.1 | -2.67 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.3 | 0.3 | 0 |
| Irritable Bowel Syndrome | 0.9 | 1.1 | -0.22 |
| ischemic stroke | 0.3 | 0.8 | -1.67 |
| Liver Cirrhosis | 1.8 | 1.1 | 0.64 |
| Long COVID | 0.6 | 1.8 | -2 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.3 | -0.3 | |
| Mast Cell Issues / mastitis | 0.6 | -0.6 | |
| ME/CFS with IBS | 0 | 0 | |
| ME/CFS without IBS | 0.3 | 0.3 | |
| Menopause | 0.5 | -0.5 | |
| Metabolic Syndrome | 1.4 | 1.2 | 0.17 |
| Mood Disorders | 1.4 | 1.8 | -0.29 |
| Multiple Sclerosis | 0.6 | 1.2 | -1 |
| Multiple system atrophy (MSA) | 0.1 | 0.3 | -2 |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 0.3 | 0.6 | -1 |
| Neuropathy (all types) | 0.3 | 0.5 | -0.67 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.8 | 1.2 | -0.5 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | |
| Obesity | 1.2 | 1.4 | -0.17 |
| obsessive-compulsive disorder | 0.5 | 0.6 | -0.2 |
| Osteoarthritis | 0.3 | -0.3 | |
| Osteoporosis | 1.1 | 1.1 | |
| Parkinson's Disease | 1.6 | 1.5 | 0.07 |
| Polycystic ovary syndrome | 1.6 | 1.3 | 0.23 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.6 | -0.6 | |
| Psoriasis | 0.3 | 0.9 | -2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.8 | 0.9 | 1 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 0.9 | 1.1 | -0.22 |
| scoliosis | 0.3 | 0.3 | 0 |
| Sjögren syndrome | 0.3 | -0.3 | |
| Sleep Apnea | 0.6 | 1.4 | -1.33 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.5 | 0.8 | -0.6 |
| Systemic Lupus Erythematosus | 0.6 | 0.8 | -0.33 |
| Tic Disorder | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.6 | 0.8 | -0.33 |
| Type 2 Diabetes | 1.7 | 1.1 | 0.55 |
| Ulcerative colitis | 1.3 | -1.3 | |
| Unhealthy Ageing | 0.7 | 0.9 | -0.29 |
| Vitiligo | 0.3 | 0 | 0 |
